Royalty Pharma Acquires Theravance Biopharma
Ticker: TBPH · Form: 8-K · Filed: Jun 2, 2025 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 8-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, completed-deal
TL;DR
Royalty Pharma just bought Theravance Biopharma for $1/share cash. Deal closed May 30.
AI Summary
On May 30, 2025, Theravance Biopharma, Inc. announced the completion of its acquisition by Royalty Pharma plc. The transaction was previously announced on March 26, 2025. Shareholders of Theravance Biopharma will receive $1.00 in cash for each share of common stock they own.
Why It Matters
This acquisition marks a significant change in ownership for Theravance Biopharma, potentially impacting its future development pipeline and strategic direction under Royalty Pharma's control.
Risk Assessment
Risk Level: medium — The acquisition is complete, but the integration and future performance of Theravance's assets under Royalty Pharma introduce ongoing risks.
Key Numbers
- $1.00 — Cash per share (Amount shareholders will receive upon acquisition.)
Key Players & Entities
- Theravance Biopharma, Inc. (company) — Registrant
- Royalty Pharma plc (company) — Acquiring entity
- May 30, 2025 (date) — Completion date of acquisition
- March 26, 2025 (date) — Date of previous announcement
- $1.00 (dollar_amount) — Cash per share
FAQ
What was the exact date of the acquisition completion?
The acquisition was completed on May 30, 2025.
Who acquired Theravance Biopharma?
Royalty Pharma plc acquired Theravance Biopharma.
What was the initial announcement date for this transaction?
The transaction was initially announced on March 26, 2025.
How much cash will Theravance Biopharma shareholders receive per share?
Shareholders will receive $1.00 in cash for each share of common stock they own.
What is Theravance Biopharma's primary business?
Theravance Biopharma is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 2, 2025 regarding Theravance Biopharma, Inc. (TBPH).